Insulin Resistance in Nonobese Patients with Polycystic Ovary SyndromeToprak S.a · Yönem A.a · Çakır B.b · Güler S.b · Azal Ö.a · Özata M.a · Çorakçı A.a
Departments of Endocrinology and Metabolism,aGülhane School of Medicine and bAnkara Education and Research Hospital, Ankara, Turkey
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objectives: Most patients with polycystic ovary syndrome (PCOS) are obese and known to have insulin resistance. Obesity per se is a cause of insulin resistance. This study was performed to determine whether insulin resistance occurs in patients with PCOS in the absence of obesity and acanthosis nigricans. Method: For this purpose, an euglycemic hyperinsulinemic clamp study was performed in 12 nonobese patients with PCOS and in 10 healthy control subjects matched for age and weight. Results: The mean serum testosterone and luteinizing hormone (LH) levels were significantly elevated (4.09 ± 1.32 vs. 1.18 ± 0.53 pg/ml, p < 0.001, and 11.63 ± 5.37 vs. 4.98 ± 2.73 mIU/ml, p < 0.001, respectively), and the serum sex hormone binding globulin level was significantly reduced (40.96 ± 14.94 vs. 73.98 ± 30.40 nmol/l, p < 0.001) in patients with PCOS as compared with the values in control subjects. The mean serum insulin level was also elevated in patients with PCOS as compared with control subjects (32.33 ± 4.98 vs. 19.56 ± 2.21 µU/ml, p < 0.05). The insulin sensitivity was lower in patients with PCOS as compared with the control subjects (200 ± 27.8 vs. 427.8 ± 88.9 µmol kg–1min–1, p < 0.001). In patients with PCOS, the serum levels of free testosterone (r = –0.89, p < 0.001) and LH were inversely correlated with the insulin sensitivity (r = –0.63, p < 0.05). Serum follicle-stimulating hormone, prolactin, and dehydroepiandrosterone sulfate levels were similar in both groups. Conclusions: These results indicate that a significant degree of insulin resistance exists in nonobese patients with PCOS and that this insulin resistance is significantly related to serum LH and free testosterone levels. Thus, measures to decrease insulin resistance may have to be considered earlier to decrease the potential risks of developing diabetes mellitus and coronary artery disease at later ages of life in these patients.
© 2001 S. Karger AG, Basel
Dunaif A: Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995;98:33–39.
- Legro RS, Finegood D, Dunaif A: A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694–2698.
- Taylor AE: Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. Am J Obstet Gynecol 1998;179:94–100.
- Goudas VT, Dumesic DA: Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1997;26:893–912.
- Kidson W: Polycystic ovary syndrome: A new direction in treatment. Med J Aust 1998;169:537–540.
- Acién P, Quereda F, Matallín P, Villarroya E, López Fernández JA, Acién M, Mauri M, Alfayate R: Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: A heterogeneous group of disorders. Fertil Steril 1999;72:32–40.
- Meirow D, Yossepowitch O, Rösler A, Brzezinski A, Schenker JG, Laufer N, Raz I: Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod 1995;10:1951–1956.
- dos Reis RM, Foss MC, de Moura MD, Ferriani RA, Silva de Sá MF: Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism. Gynecol Endocrinol 1995;9:45–50.
- Tropeano G, Vuolo IP, Lucisano A, Liberale l, Barini A, Carfagna P, Caroli G, Menini E, Dell’ Acqua S: Gonadotropin levels in women with polycystic ovary syndrome: Their relationship to body weight and insulin levels. J Endocrinol Invest 1996;19:139–145.
- De Fronzo RA, Tobin JD, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–E223.
Copeland KC, Kenney FA, Nair KS: Heated dorsal vein sampling for metabolic studies: A reappraisal. Am J Physiol 1992;263:E1010–E1014.
- Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113–116.
- Gibson M, Schiff I, Tulchinsky D, Ryan K: Characterization of hyperandrogenism with insulin resistant diabetes type A. Fertil Steril 1980;33:501.
Pasquali R, Venturoli S, Paradis R, Capelli M, Parenti M: Insulin and c-peptide levels in obese patients with polycystic ovaries. Horm Metab Res 1982;14:284 .
- Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K: Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999;71:323–327.
- Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield R, Polonsky KS: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108–2116.
- Cara JF, Rosenfield RL: Insulinlike growth factor 1 and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988;123:733–739.
- Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillenjo T: Regulation of androgen production in cultured human thecal cells by insulin-like growth factor 1 and insulin. Fertil Steril 1993;59:323–331.
- Jaffiol C, Rouard M, Macari F, Lautier C, Ait el Mkadem S, Méchaly I, Brun JF, Renard E, Cros G, Bringer J, Grigorescu F: Insulin resistance: From clinical diagnosis to molecular genetics. Implications in diabetes mellitus. Bull Acad Natl Méd 1999;183:1761–1777.
- Book CB, Dunaif A: Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110–3116.
- Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z: Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327:157–162.
- Rosenfield RL, Barnes RB, Ehrmann DA: Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1686–1692.
- Rosenfield RL, Barnes RB, Cara JF, Lucky AW: Dysregulation of cytochrome P450c17 alpha as the cause of polycystic ovary syndrome. Fertil Steril 1990;53:785–791.
- Ünlühizarci K, Keleştimur F, Şahin Y, Bayram F: The treatment of insulin resistance does not improve adrenal cytochrome P450c17 alpha enzyme dysregulation in polycystic ovary syndrome. Eur J Endocrinol 1999;140:56–61.
- Ünlühizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A: The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999;51:231–236.
- Plymate SR, Matej LA, Jones RE, Friedl KE: Inhibition of sex hormone-binding globulin in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988;67:460–464.
- Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89.
- Nahum R, Thong KJ, Hillier SG: Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod 1995;10:75–81.
- Berga SL, Guzick DS, Winters SJ: Increased luteinizing hormone and α-subunit secretion in women with hyperandrogenic anovulation. J Clin Endocrinol Metab 1993;77:895–901.
- Adashi EY, Hsueh AJW, Yen SSC: Insulin enhancement of luteinizing hormone and follicle stimulating hormone release by cultured pituitary cells. Endocrinology 1981;108:1441–1449.
- Givens JR, Andersen RN, Umstat ES, Wiser WL: Clinical findings and hormonal responses in patients with polycystic ovarian disease with normal versus elevated LH levels. Obstet Gynecol 1976;47:388–394.
- Yen SS, Laughlin GA, Morales AJ: Interface between extra- and intraovarian factors in polycystic ovarian syndrome. Ann NY Acad Sci 1993;687:98–111.
- Unger JW, Livingston JN, Moss AM: Insulin receptors in the central nervous system: Localization, signaling mechanisms and functional aspects. Prog Neurobiol 1991;36:343–362.
- Tropeano G, Lucisano A, Liberale I, Barini A, Iole PV, Martino G, Menini E, Dell’Acqua S: Insulin, c-peptide, androgens and β-endorphin response to oral glucose in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1994;78:305–309.
- Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R, Nawata H: Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 2000;271:710–713.
- Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve Smith L: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999;48:511–519.
- Açbay O, Gündogdu S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:946–949.
- Morin Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691–696.
Velázquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome Obstet Gynecol 1997;90:392–395.
- Gilling Smith C, Watson H, Willis D: Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361–781.
- Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299–3306.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.